ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for monitor Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.

TENX Tenax Therapeutics Inc

3.09
0.00 (0.00%)
Pre Mercado
Última actualización: 03:47:51
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Tenax Therapeutics Inc TENX NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
0.00 0.00% 3.09 03:47:51
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
3.09
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
13/6/202415:32EDGAR2Form 8-K - Current report
24/5/202415:31EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
21/5/202416:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/5/202416:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/5/202415:01EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
14/5/202408:01EDGAR2Form 8-K - Current report
14/5/202407:00GLOBETenax Therapeutics Reports First Quarter 2024 Financial..
30/4/202406:30GLOBETenax Therapeutics Announces New U.S. Patent Covering the..
09/4/202407:30GLOBETenax Therapeutics to Host KOL Event: “LEVEL Setting: the..
28/3/202407:30GLOBETenax Therapeutics Provides Business and Clinical..
12/3/202407:30GLOBETenax Therapeutics to Present at the 36th Annual Roth..
29/2/202408:00GLOBETenax Therapeutics Announces Oral Presentation of..
23/2/202415:30EDGAR2Form 8-K - Current report
20/2/202415:01EDGAR2Form SC 13G - Statement of acquisition of beneficial..
20/2/202407:33EDGAR2Form 8-K - Current report
20/2/202407:30GLOBETenax Therapeutics Announces Global License Amendment that..
16/2/202410:28EDGAR2Form SC 13G - Statement of acquisition of beneficial..
15/2/202418:36EDGAR2Form SC 13G - Statement of acquisition of beneficial..
12/2/202415:46EDGAR2Form 8-K - Current report
08/2/202407:16GLOBETenax Therapeutics Announces Pricing of Approximately $9..
07/2/202423:15EDGAR2Form EFFECT - Notice of Effectiveness
07/2/202419:01GLOBETenax Therapeutics Enrolls First Patient in Phase 3 LEVEL..
06/2/202407:56EDGAR2Form 8-K - Current report
06/2/202407:30GLOBETenax Therapeutics Announces USPTO Grants Notice of..
02/2/202416:24EDGAR2Form S-1/A - General form for registration of securities..
01/2/202415:20EDGAR2Form S-1/A - General form for registration of securities..
19/1/202415:30EDGAR2Form 8-K - Current report
12/1/202416:46EDGAR2Form 3 - Initial statement of beneficial ownership of..
12/1/202415:30EDGAR2Form 8-K - Current report
05/1/202415:46EDGAR2Form 8-K - Current report
01/12/202315:47EDGAR2Form S-1 - General form for registration of securities under..
01/12/202315:01EDGAR2Form 8-K - Current report
17/11/202307:30GLOBETenax Therapeutics Announces Professor Javed Butler, M.D.,..
14/11/202315:31EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
13/11/202315:31EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
13/11/202308:10EDGAR2Form 8-K - Current report
13/11/202307:30GLOBETenax Therapeutics Announces FDA Clearance of IND for..
29/9/202315:11EDGAR2Form 8-K - Current report
15/8/202315:05EDGAR2Form 8-K - Current report
14/8/202315:07EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
19/7/202315:30EDGAR2Form 8-K - Current report
19/7/202307:30GLOBETenax Therapeutics Issued U.S. Patent for Oral Levosimendan..

Su Consulta Reciente

Delayed Upgrade Clock